Biotherapies in large vessel vasculitis
G Pazzola1, F Muratore1, N Pipitone1
1Rheumatology Unit, Department of Internal Medicine, Azienda Ospedaliera ASMN, Istituto di Ricovero e Cura a Carattere Scientifico, Viale Risorgimento, 80, 42123 Reggio Emilia, Italy.
Abstract:
The mainstay of therapy of large vessel vasculitides (LVV) remains glucocorticoids (GC). Although most patients initially achieve disease remission, relapses and GC dependence are seen in more than two-thirds of cases. Conventional synthetic disease-modifying antirheumatic drugs (DMARDs) showed little or no steroid sparing effects, while biological agents represent a valid therapeutic option in patients with severe and/or relapsing LVV.
Related Concept Videos
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Venous Thrombosis III: Interprofessional Care
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Peripheral Artery Disease III: Interprofessional Care
Myocarditis III: Medical Management
Tumor Immunotherapy


